Kenai Therapeutics raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation and Cure Ventures to advance next generation allogeneic cell therapies for neurological diseases.
Amount Raised
$82 Million
Round Type
Series A
San DiegoBiotechnologyHealth CareTherapeuticsInvestors
Description
Kenai Therapeutics announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. The funding will enable the Company to submit an IND for RNDP-001 and complete Phase 1 clinical trials for the treatment of Parkinson’s disease.
Quick answer
Kenai Therapeutics raised $82 Million in a Series A round, dated February 29, 2024. Investors: Alaska Permanent Fund Corporation, Euclidean Capital, Saisei Ventures, Cure Ventures and The Column Group. Kenai Therapeutics is based in San Diego, California, United States.
- How much did Kenai Therapeutics raise?
- Kenai Therapeutics raised $82 Million in a Series A round on February 29, 2024.
- Who invested in Kenai Therapeutics?
- Alaska Permanent Fund Corporation, Euclidean Capital, Saisei Ventures, Cure Ventures and The Column Group are named as investors in this round.
- What does Kenai Therapeutics do?
- Kenai Therapeutics is a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders.
- Where is Kenai Therapeutics based and how big is it?
- Kenai Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Kenai Therapeutics?
- Fundz holds 1 contact at Kenai Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Kenai Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- FundaMental Pharma raised $14M (Seed) on April 11, 2024.
- TORL BioTherapeutics raised $158M (Series B) on April 10, 2024.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- D3 Bio raised $62M (Series A) on April 8, 2024.
- Beacon Therapeutics raised $120M (Series A) on April 5, 2024.
- TORL BioTherapeutics raised $158M on April 4, 2024.
Who to call at Kenai Therapeutics, and when
A new round usually means Kenai Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kenai Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kenai Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kenai Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kenai Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKenai Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.